Fibrous dysplasia happens when abnormal fibrous (scar-like) tissue replaces healthy bone. The fibrous tissue weakens the bone over time, which can lead to fractures (breaks) and misshapen bones.

Some people with fibrous dysplasia have no symptoms, or only a few symptoms, usually in one bone (monostotic). Other people may have multiple affected bones (polyostotic) and experience more symptoms. The disease may occur alone or as part of a condition known as McCune-Albright syndrome, which affects the bone as well as the skin and endocrine (hormone-producing) tissues.

Unfortunately, there is no cure for fibrous dysplasia; however, treatments may help to relieve pain, and supportive measures such as physical therapy may help strengthen muscle and improve range of motion.

What happens in fibrous dysplasia?

Fibrous dysplasia happens when a gene mutates (changes) while the baby is developing in the womb. The changes in the gene cause bone-forming cells to fail to mature. Instead, they produce abnormal fibrous tissue in certain bones. Because the gene change happens while the baby is developing, only specific bones will have the disease. This means fibrous dysplasia does not spread from one bone to another.

The disease can affect any bone in the body; however, for some people, it occurs in the bones on one side of the body. The most common bones affected by fibrous dysplasia include:

• Skull and facial bones.
• Femur (upper leg) and tibia and fibula (lower leg).
• Humerus (upper arm bone).
• Pelvis.
• Ribs.

Fibrous dysplasia is a skeletal disorder that is characterized by the replacement of normal bone with fibrous bone tissue. It may involve one bone (monostotic) or multiple bones (polyostotic). Fibrous dysplasia can affect any bone in the body. The most common sites are the bones in the skull and face, the long bones in the arms and legs, the pelvis, and the ribs. Though many people with this disorder do not have any symptoms, others may have bone pain, abnormally shaped bones (deformities), or an increased risk of fractures (broken bones). The problems a person experiences depend on which bones are affected, and may arise from compression and displacement of adjacent structures to the lesions. For example, the legs can be of different lengths, leading to a limp, the bones of the sinuses can be affected, leading to chronicsinus congestion or headache.

This condition can occur alone or as part of a genetic disorder, such as McCune-Albright syndrome. While there is no cure for fibrous dysplasia, the symptoms can be treated. Medications known as bisphosphonates can reduce pain and surgery may be used to treat fractures or to correct misshapen bones.

ABSTRACT

Fibrous dysplasia (FD) is an uncommon mosaic disorder falling along a broad clinical spectrum. It arises from post-zygotic mutations in GNAS, resulting in constitutive activation of the cAMP pathway-associated G-protein, G_sα, and proliferation of undifferentiated skeletal progenitor cells. FD may occur in isolation, or in association with skin pigmentation and hyperfunctioning endocrinopathies, termed McCune-Albright syndrome (MAS). Disease may involve any part or combination of the skeleton, ranging from an isolated, asymptomatic monostotic lesion, to severe polyostotic disease resulting in fractures, deformity, functional impairment, and progressive scoliosis. FD may be diagnosed clinically in patients with polyostotic disease and/or extraskeletal features of MAS; however, biopsy is typically required to diagnose monostotic disease. Management is focused on treating endocrinopathies, preventing fractures, optimizing function, and treating pain. All patients should be evaluated and treated for extraskeletal features of MAS at the time of diagnosis. In particular control of growth hormone excess is important to prevent craniofacial FD expansion, and control of FGF23-mediated hypophosphatemia is important to prevent fracture, deformity, and bone pain. A mainstay of FD treatment is surgical, and practitioners should be aware that techniques and procedures used in other skeletal disorders, such as bone grafting and prophylactic optic nerve decompression, are frequently ineffective in FD. There are currently no medical therapies capable of altering the disease course in FD. Bisphosphonates may be effective in treating FD-related bone pain but are unlikely to impact bone quality or lesion expansion. There is a critical need to develop novel therapies capable of altering the disease activity of FD lesions. Ongoing efforts include developing drugs to target the mutant G_sα, and devising strategies for targeting mutant skeletal progenitor cells. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.

INTRODUCTION

Fibrous dysplasia of bone (FD) (OMIM#1174800) is an uncommon skeletal disorder resulting in fractures, pain, and functional impairment. Disease is mosaic and may occur in a single bone (monostotic) or multiple bones (polyostotic). FD thus falls along a broad clinical spectrum, ranging from an incidental, asymptomatic lesion to severe disabling disease. Lesions may occur in isolation or in association with extraskeletal features, most commonly café-au-lait skin macules and hyperfunctioning endocrinopathies including precocious puberty, hyperthyroidism, growth hormone excess, hypercortisolism, and fibroblast growth factor-23 (FGF23)-mediated hypophosphatemia. The combination of FD and/or any of these extraskeletal features is termed McCune-Albright syndrome (MAS).

PATHOGENESIS

FD/MAS results from post zygotic somatic activating (gain-of-function) mutations in GNAS, which encodes the cyclic AMP pathway-associated G-protein, G_sα. GNAS mutations in FD/MAS are known to occur at one of two amino acid residues: Arg201 (>95% of reported cases) or Gln227 (5%). These mutations disrupt the intrinsic GTPase activity of G_sα, causing constitutive activation of adenylyl cyclase and inappropriate cyclic AMP signaling. Involvement of the skin, bone, and endocrine systems is consistent with a mutational event early in embryogenesis, occurring prior to derivation of the 3 germ layers. The phenotype in individuals with FD/MAS is thus the result of the distribution of tissues containing the GNAS mutation, and the role played by G_sα signaling in those tissues. This mosaicism is reflected in the clinical features of FD/MAS, including the distinctive appearance of café-au-lait macules which follow developmental lines of Blaschko (Fig 1A), the patchy bone disease (Fig 1B) with extreme variability between individuals, and the lack of any reported cases of vertical transmission.

The pathogenesis of FD results from replacement of normal bone and bone marrow by fibro-osseous lesions. Histologically lesions are comprised of skeletal progenitor cells, which proliferate in the multipotent state without the expected differentiation into osteoblast, adipocyte, and hematopoietic-supporting cell lines. Skeletal progenitor cell proliferation and abnormal bone formation result in the characteristic histologic features of FD, including marrow fibrosis, abnormally-shaped trabeculae, and abnormal skeletal matrix formation (Fig 2). Also characteristic is skeletal undermineralization with prominent osteoid, due in part to increased production of FGF23 by FD cells.

Figure 1.

Clinical and radiographic features of fibrous dysplasia/McCune-Albright syndrome. A. Fibrous dysplasia involving the lower extremities has resulted in a windswept deformity and impaired ambulation. Note the café-au-lait macules (white arrowheads) on the posterior trunk with characteristic jagged borders and location respecting the midline of the body. B. Technetium-99 bone scan shows patchy tracer uptake in affected areas in the skull and limbs (black arrows). C. Radiograph of a patient with axial fibrous dysplasia resulting in severe thoracolumbar scoliosis.

Figure 2.

Histopathologic features of fibrous dysplasia. Hematoxylin-eosin stained sections in low (A) and high power (B) show irregular, discontinuous trabeculae (b) within a fibrous stroma (ft), demonstrating the typical “discontinuous pattern. Goldner’s trichrome stained sections in low (C) and high power (D) reveal osteomalacic changes including excess osteoid (asterisks) and severe undermineralization of the dysplastic bone.

CLINICAL FEATURES

The clinical features in individuals with FD are variable depending upon the location and extent of skeletal lesions. The most commonly involved areas are the proximal femurs and skull base; however, any combination of affected bones is possible. FD in the appendicular skeleton often presents with fractures, limp, and/or pain. Recurrent fractures and FD expansion may lead to deformity with pain and loss of ambulation (Fig 1A). In the craniofacial area FD may present with facial asymmetry or a painless “lump” in the skull. Progressive expansion of craniofacial lesions may rarely lead to functional deficits including vision loss, malocclusion, and obstruction of the nasal and otic canals. Rarely, cranial base deformities may lead to serious neurologic complications. Axial FD commonly leads to scoliosis, which in rare cases may be progressive and potentially fatal  (Fig 1C).

Radiographic features of FD also vary depending upon location. In the appendicular skeleton lesions appear radiolucent with cortical thinning and a characteristic “ground glass” appearance (Fig 3A). Craniofacial FD may appear sclerotic on radiographs, while computed tomography shows expansile lesions with a homogeneous “ground glass” appearance (Fig 3B). In older individuals craniofacial FD may appear more heterogeneous with focal cystic and sclerotic areas (Fig 3C).

Figure 3.

Radiographic appearance of fibrous dysplasia (FD). A. Extensive FD involvement of the bilateral femurs in an 11-year-old girl demonstrates the characteristic radiographic findings, including the homogeneous “ground glass” appearance, diffuse cortical thinning, and coxa vara (“shepherd’s crook”) deformities (white arrows). B. Computed tomography images of craniofacial FD from a 10-year-old girl demonstrate the typical homogeneous, “ground glass” appearance. White arrows indicate the optic nerves, which are encased in FD. C. Computed tomography images from the same patient at age 19 years demonstrates typical age-related changes, including the development of mixed solid and radiolucent, cystic-appearing lesions. As is typical in FD, this patient has had persistently normal vision despite encasement of the optic nerves.

The natural course of FD is to progress during childhood and adolescence. Patients have grossly normal skeletal development in utero, without obvious features of bone disease at birth. Skeletal lesions appear during the first several years of life and expand during linear growth. The majority of FD lesions are apparent by age 10 years, typically with no new clinically significant lesions occurring after age 15 years. FD lesions typically become less active in adulthood, which is mirrored histologically by age-dependent apoptosis of GNAS mutation-bearing cells in older patients, and biochemically by a progressive decline in bone turnover markers over time.

Malignant transformation occurs rarely in FD, consistent with the slight increased oncogenic potential associated with GNAS mutations. Malignancies appear to be more common in patients exposed to ionizing radiation, including those receiving pituitary radiation for treatment of growth hormone excess. Clinicians should be alerted to the possibility of malignant transformation in lesions that are rapidly expanding or show signs of cortical disruption on radiographs. Another potential complication of FD is aneurysmal bone cysts, which typically present with acute onset of expansion and localized pain. These lesions may progress rapidly, and frequently require urgent surgical treatment.

EVALUATION AND MANAGEMENT

FD is typically diagnosed based on clinical and radiologic evaluation. All patients with FD should undergo a complete skeletal evaluation at the time of diagnosis to determine the extent of the disease. This is best accomplished with technetium-99 scintigraphy or ¹⁸F-NaF PET/CT imaging to identify the areas of involvement, followed by radiographs of affected areas to better visualize lesions anatomically.

The differential diagnosis in patients with FD/MAS is variable depending upon the clinical presentation. Patients with prominent skin findings may be misdiagnosed with neurofibromatosis type 1 (NF-1), which also presents with café-au-lait macules and skeletal abnormalities. The location and distribution of skin lesions in NF-1 includes multiple smooth-bordered macules, which are generally distinct from the jagged bordered lesions in MAS that typically respect the midline of the body. Skeletal findings in NF-1 are less common and include tibial pseudoarthroses and kyphoscoliosis. There are multiple types of fibro-osseous lesions with similar radiographic and histologic features to FD, including ossifying fibromas, osteofibrous dysplasia, and giant cell tumors of bone. These lesions are generally solitary and not associated with extraskeletal features.

The utility of molecular testing for diagnostic purposes should be considered on a case-by-case basis. GNAS mutation detection is highly variable depending upon the level of mosaicism and the sensitivity of the sequencing technique. In patients with monostotic FD and no additional features of MAS, mutation testing may be helpful in distinguishing FD from other fibro-osseous skeletal lesions. In patients with polyostotic disease and/or typical extraskeletal features of MAS, mutation testing is not required to establish the diagnosis, and is unlikely to inform clinical management.

Management in FD is focused on treating endocrinopathies, preventing fractures, optimizing function, and treating pain. There are currently no medical therapies which are capable of altering the disease course. Orthopedic surgery is an important component of management however, practitioners should be aware that techniques used in other skeletal disorders may be unsuccessful in FD. In particular bone grafting, curettage, and external fixation are commonly used techniques that were previously considered standard in FD, but are now known to be frequently ineffective. Diagnosis and treatment of scoliosis is extremely important, as it may be rapidly progressive and lead to fatal respiratory compromise. Surgical fusion has been shown to be effective in treating FD patients with progressive scoliosis.

Surgical management of craniofacial FD lesions should similarly be approached cautiously, as complete resection is typically not possible, and partially resected lesions frequently regrow post-operatively. Optic canal involvement is common but only rarely leads to vision loss (Fig 3). Conservative management of optic canal FD has been shown to be superior in asymptomatic patients; prophylactic decompression without objective evidence of optic neuropathy may lead to vision loss and is contraindicated. All patients with craniofacial FD should undergo baseline and yearly ophthalmologic, otolaryngologic, and audiologic evaluations. Patients with FD involving the skull base should also be undergo screening imaging for cranial base deformities around skull age, and should be evaluated regularly for associated neurologic symptoms.

Evaluation and treatment for extraskeletal features of MAS is an important component of clinical management in FD. Patients should undergo a staging workup at the time of diagnosis, including complete history and physical examination, review of growth curves, biochemical testing for endocrinopathies, and ultrasonography of the thyroid and testes.

Hyperthyroidism may have a deleterious effect on bone density, increasing the risk of skeletal deformities in patients with FD. Hyperthyroidism is treated with anti-thyroidal drugs and thyroidectomy. Peripheral precocious puberty results in increased linear growth and premature epiphyseal maturation, which may compromise final adult height. Symptoms are generally well-controlled with the aromatase inhibitor letrozole in girls, which may be used in combination with a testosterone blocker in boys, as well as leuprolide in children with co-existent central precocious puberty. Growth hormone excess has been shown to increase FD expansion, particularly in the craniofacial region, leading to an increased risk of macrocephaly and vision loss. This risk may be partially ameliorated with early diagnosis and treatment. Therapeutic options include somatostatin analogues and pegvisomant, with total hypophysectomy generally reserved for refractory cases.

FGF23-mediated hypophosphatemia may have a significant impact on disease severity in FD. Although urinary phosphate wasting is common in FD patients, frank hypophosphatemia occurs less frequently due to a compensatory increase in cleavage of FGF23 into its inactive fragments. The degree of FGF23 overproduction appears to be related to overall disease burden, with frank hypophosphatemia occurring more frequently in individuals with greater amounts of FD. The course of FGF23-mediated hypophosphatemia in any individual may therefore be variable, with low phosphate levels “unmasked” during periods of rapid growth or disease progression. Hypophosphatemia may also potentially normalize as growth and disease activity wanes. In addition to the classic rachitic findings of growth deceleration and long bone deformities, FD patients with uncontrolled hypophosphatemia are also at higher risk for fractures, deformities and bone pain. Treatment is similar to other disorders of FGF23 excess, and includes oral phosphorus and calcitriol.

Bone pain is a common feature of FD, and pain management is an important component of clinical care. The pathophysiology of FD-related bone pain is not well-understood, and there does not appear to be a clear relationship between pain and overall FD burden. The prevalence and severity of pain is generally greater in adults, however pain is frequently unrecognized and untreated in children. In patients who present with pain, it is important to exclude acute injury, impending fracture, or other causes that may require orthopedic intervention. Patients should also be evaluated and treated for hypophosphatemia, in which pain is frequently the presenting symptom. In the absence of structural or metabolic causes, a reasonable management strategy for bone pain is to use a step-wise approach, starting with conservative measures such as non-steroidal anti-inflammatory medications, rest, and application of heat or cold packs. In pain not responsive to conservative measures, intravenous bisphosphonates such as zoledronic acid or pamidronate may be helpful. In general, these should be administered based on symptoms rather than a set schedule, using the lowest effective dose and interval.

A number of reports have investigated the efficacy of bisphosphonates, medications which increase bone density by inhibiting bone-resorbing osteoclasts, as a potential treatment for FD. Early uncontrolled case series reported subjective improvements in pain and variable effects on the radiographic appearance of FD lesions. A placebo-controlled trial of the oral bisphosphonate alendronate showed no effects on pain or FD lesion appearance. Retrospective analyses have demonstrated that bisphosphonates do not appear to prevent progression of FD lesions in children, and do not appear to prevent progression of spinal deformity in patients with scoliosis. Concerningly, osteonecrosis of the jaw has been reported in patients with FD, with a prevalence of 5.4% in one series. The role of bisphosphonates in FD management has not been fully elucidated; however, at present there is little evidence to support any effect of bisphosphonates on FD quality or lesion expansion, and the author recommends their use be limited to treatment of bone pain.

FUTURE DIRECTIONS

Current therapeutic options for treatment of FD are inadequate, and there is a critical need to develop medical therapies capable of altering the disease course. Ongoing efforts include developing drugs to target activity of the mutant G_sα, and devising strategies for targeting mutant skeletal progenitor cells. Recent evidence suggests a possible role for denosumab, a monoclonal inhibitor of receptor activator of nuclear kappa-B ligand, for treatment of FD. This medication has been approved for treatment of giant cell tumors, and showed preliminary positive effects on bone turnover and pain in case reports of FD. Of concern are severe, life-threatening metabolic derangements associated with denosumab treatment in one FD patient. Currently there is insufficient evidence to support safety or efficacy of denosumab treatment for FD, and its use should be limited to research protocols.

ACKOWLEDGEMENTS

This research was supported by the Intramural Research Program of the NIH, NIDCR.

Monostotic fibrous dysplasia is the least complicated type of fibrous dysplasia. It affects only one bone and most often occurs in the ribs, thigh bone, shin bone, or one of the facial bones. For the polyostotic form, the lesions often occur in younger patients and can involve numerous bones, sometimes more than half of the bones in the skeletal system.

The most common sites in polyostotic fibrous dysplasia include the skull, face, thigh bone, shin bones, upper arm, pelvis, and ribs. Although when multiple bones are affected, they are often found on one side of the body, the disease does not "spread" from one bone to another. In fact, the pattern in which bones are involved is established very early in life and does not change with age.

Fibrous dysplasia is not common, but anyone can develop the disease. It is usually diagnosed in children and young adults; however, it was probably present but not diagnosed at birth. Race, sex, environmental exposures, and geographic location do not influence who develops the disease.

The cause of fibrous dysplasia has been linked to a gene mutation that occurs after conception, in the early stages of fetal development. The mutation involves a gene that affects the cells that produce bone. People with fibrous dysplasia carry this mutation in some, but not all cells of their body. It is not well understood why the mutation occurs, but it is not inherited from a parent, nor can it be passed on from parents to children.

People with a milder form of the disease may not have any symptoms and do not learn they have fibrous dysplasia until they have an x-ray for another reason. Other people may have a more severe form of the disease and develop symptoms in early childhood. The most common symptoms of fibrous dysplasia include:

• Bone pain, which may happen because of fractures or fibrous tissue changes in the bones.
• Misshapen bones or bowing of bones. This is most common in the femur (thigh bone) and is called a coxa vara (shepherd’s crook).
• Fractures due to weak bone structure.

Other symptoms may develop depending on which bones are affected. Changes in the:

• Leg bones may cause the bones to shorten, bow, or change in length, leading to a limp or changes in mobility.
• Facial bones and sinuses can cause long-term sinus congestion.
• Spine can lead to scoliosis.
• Skull and facial bones around the eyes and ears may rarely lead to vision and hearing loss.

In very rare cases, some people may develop a malignant form of bone cancer.

Depending on the location and severity of symptoms, your doctor may order one of the following tests:

• X-rays. This is the most common test that doctors use to diagnose fibrous dysplasia. An x-ray can evaluate the bone structure for the disease and diagnose fractures and misshapen bones.
• Magnetic resonance imaging (MRI) or computed tomography (CT). These tests provide detailed images that are analyzed by a computer and are helpful in evaluating the skull and facial bones for the disease.
• Bone scan. This test evaluates the entire skeleton, helping doctors understand the amount of bone in the body affected by the disease.
• Bone biopsy. During this test, a doctor takes a small amount of bone tissue from an area affected by the disease to examine under a microscope.

Some children may need additional testing to determine if fibrous dysplasia is part of another syndrome or disorder. Genetic testing is usually performed on a case-by-case basis.

There is no cure for fibrous dysplasia. The goals for treatment may include:

• Treating and preventing fractures.
• Correcting misshapen bones when the bowing is severe.
• Managing pain.

If you or your child do not have any symptoms and are not at risk for a facture, your doctor may recommend monitoring the condition. If symptoms exist, treatments may include:

• Physical therapy to help strengthen muscle and improve range of motion.
• Cast, splint, or brace to immobilize fractures or improve mobility.
• Surgery to prevent and repair fractures, treat scoliosis, and repair misshapen bone.

Although there are no medicines approved by the U.S. Food and Drug Administration to treat fibrous dysplasia, your doctor may recommend a therapy approved for a related condition. Your doctor may prescribe:

• Pain medicines to treat pain caused by broken bones and chronic bone pain.
• Medicines to treat the hormone problems some patients with fibrous dysplasia may have.

You or your child may see different health care professionals, depending on the location of the disease and the severity of the symptoms. Most people work with a team of doctors and medical professionals, which may include:

• Orthopaedists, who treat and perform surgery for bone and joint diseases.
• Dental providers such as dentists and oral-maxillofacial surgeons, who provide dental care and treat problems of the mouth and jaw.
• Endocrinologists, who treat bone problems and problems related to the glands and hormones.
• Mental health providers, who provide counseling and treat mental health disorders.
• Occupational therapists, who teach how to safely perform activities of daily living.
• Ophthalmologists, who specialize in treating disorders and diseases of the eye.
• Otolaryngologists, who treat ear, nose, and throat disorders.
• Physiatrists, who specialize in physical and rehabilitation medicine.
• Physical therapists, who teach ways to build muscle strength, recover from broken bones, and prevent broken bones
• Primary care physicians, who diagnose and treat adults and children.

When possible, try to work with health care professionals familiar with treating fibrous dysplasia.

Living with fibrous dysplasia is different for each person. Some people have few or no symptoms, while others have many symptoms that affect their ability to perform daily activities. The following tips may help.

• See your health care providers on a regular basis to help keep bones as healthy as possible.
• Talk to your doctor or physical therapist about which types of exercises are best.
• Ask your doctor about taking calcium, vitamin D, and phosphorus supplements to support general bone health.
• Ask family and friends for help when you need it.
• Reach out to online and community support groups.